Research programme: ATR protein inhibitors - Merck Serono/Spanish National Cancer Research Centre
Latest Information Update: 23 Dec 2013
At a glance
- Originator Spanish National Cancer Research Centre
- Developer Merck Serono; Spanish National Cancer Research Centre
- Mechanism of Action ATR protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Dec 2013 Preclinical trials in Cancer in Switzerland (unspecified route)
- 18 Dec 2013 Preclinical trials in Cancer in Spain (unspecified route)